Journal of breath research · 2026
Diagnosing pathogenic DNA from Pneumocystis Jirovecii in exhaled breath condensate: a feasibility study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Christensen Sophie Rex, Lundsted Ditte Helene, Nørholt Ditte Høgh, Jensen Emilie, Wittrup Julie, Abou-Harb Jonas Johnsen, Stentoft Victoria, Fuglsang-Damgaard David, Gade Inger Lise
Аннотация
BACKGROUND: Pathogen identification in pneumonia is achieved in less than 25% of cases. Diagnosis of pneumocystis pneumonia relies on a multimodal approach combining clinical, radiological, and immunological assessment with microbiological confirmation, most often by polymerase chain reaction. However, the method cannot reliably distinguish between active infection and colonization because of limited assay standardization and lack of universally accepted interpretive criteria. This pilot study explored whether Pneumocystis jirovecii DNA could be detected in patients with suspected infection (PcP) in exhaled breath condensate (EBC).
METHODS: Ten patients with suspected PcP and ten healthy controls provided oral mouthwash (OW) and EBC samples for real-time PCR.
RESULTS: P. jirovecii DNA was detected in both OW and EBC in four patients. Ongoing PcP therapy correlated with absence of detectable DNA (p = 0.048).
CONCLUSION: Detecting P. jirovecii DNA in EBC is feasible, supporting its potential as a non-invasive diagnostic and monitoring tool.
TRIAL REGISTRATION: The study was approved by the North Denmark Regional Committee on Health Research Ethics (Journal number N-20190070).
METHODS: Ten patients with suspected PcP and ten healthy controls provided oral mouthwash (OW) and EBC samples for real-time PCR.
RESULTS: P. jirovecii DNA was detected in both OW and EBC in four patients. Ongoing PcP therapy correlated with absence of detectable DNA (p = 0.048).
CONCLUSION: Detecting P. jirovecii DNA in EBC is feasible, supporting its potential as a non-invasive diagnostic and monitoring tool.
TRIAL REGISTRATION: The study was approved by the North Denmark Regional Committee on Health Research Ethics (Journal number N-20190070).